Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30
Benzinga Newsdesk 2 months ago
NewsInitiationAnalyst RatingsPrice Target
Citigroup analyst Yigal Nochomovitz initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Buy rating and announces Price Target of $30.
Citigroup analyst Yigal Nochomovitz initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Buy rating and announces Price Target of $30.